#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project


Background:
Approximately 800,000 children die each year due to pneumococcal disease and >90% of these deaths occur in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and introduction policies. The aim of this study was to systematically estimate the global and regional distributions of serotypes causing IPD in children <5 years of age.

Methods and Findings:
We systematically reviewed studies with IPD serotype data among children <5 years of age from the published literature and unpublished data provided by researchers. Studies conducted prior to pneumococcal conjugate vaccine (PCV) introduction, from 1980 to 2007, with ≥12 months of surveillance, and reporting ≥20 serotyped isolates were included. Serotype-specific proportions were pooled in a random effects meta-analysis and combined with PD incidence and mortality estimates to infer global and regional serotype-specific PD burden. Of 1,292, studies reviewed, 169 were included comprising 60,090 isolates from 70 countries. Globally and regionally, six to 11 serotypes accounted for ≥70% of IPD. Seven serotypes (1, 5, 6A, 6B, 14, 19F, 23F) were the most common globally; and based on year 2000 incidence and mortality estimates these seven serotypes accounted for >300,000 deaths in Africa and 200,000 deaths in Asia. Serotypes included in both the 10- and 13-valent PCVs accounted for 10 million cases and 600,000 deaths worldwide.

Conclusions:
A limited number of serotypes cause most IPD worldwide. The serotypes included in existing PCV formulations account for 49%–88% of deaths in Africa and Asia where PD morbidity and mortality are the highest, but few children have access to these life-saving vaccines.

: Please see later in the article for the Editors' Summary


Vyšlo v časopise: Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Med 7(10): e32767. doi:10.1371/journal.pmed.1000348
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000348

Souhrn

Background:
Approximately 800,000 children die each year due to pneumococcal disease and >90% of these deaths occur in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and introduction policies. The aim of this study was to systematically estimate the global and regional distributions of serotypes causing IPD in children <5 years of age.

Methods and Findings:
We systematically reviewed studies with IPD serotype data among children <5 years of age from the published literature and unpublished data provided by researchers. Studies conducted prior to pneumococcal conjugate vaccine (PCV) introduction, from 1980 to 2007, with ≥12 months of surveillance, and reporting ≥20 serotyped isolates were included. Serotype-specific proportions were pooled in a random effects meta-analysis and combined with PD incidence and mortality estimates to infer global and regional serotype-specific PD burden. Of 1,292, studies reviewed, 169 were included comprising 60,090 isolates from 70 countries. Globally and regionally, six to 11 serotypes accounted for ≥70% of IPD. Seven serotypes (1, 5, 6A, 6B, 14, 19F, 23F) were the most common globally; and based on year 2000 incidence and mortality estimates these seven serotypes accounted for >300,000 deaths in Africa and 200,000 deaths in Asia. Serotypes included in both the 10- and 13-valent PCVs accounted for 10 million cases and 600,000 deaths worldwide.

Conclusions:
A limited number of serotypes cause most IPD worldwide. The serotypes included in existing PCV formulations account for 49%–88% of deaths in Africa and Asia where PD morbidity and mortality are the highest, but few children have access to these life-saving vaccines.

: Please see later in the article for the Editors' Summary


Zdroje

1. World Health Organization 2008 The global burden of disease: 2004 update Geneva World Health Organization

2. O'BrienKL

WolfsonLJ

WattJP

HenkleE

Deloria-KnollM

2009 The global burden of disease due to Streptococcus pneumoniae in children less than 5 years of age. Lancet 374 893 902

3. HausdorffWP

BryantJ

ParadisoPR

SiberGR

2000 Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30 100 121

4. CherianT

2007 WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26–27 October 2006, Geneva. Vaccine 25 6557 6564

5. World Health Organization 2009 Global literature review of Haemophilus influenzae type b and Streptococcus pneumoniae invasive disease among children less than five years of age 1980–2005 Geneva World Health Organization

6. DerSimonianR

LairdN

1986 Meta-analysis in clinical trials. Controlled Clinical Trials 7 177 188

7. United Nations Population Division World Population Prospects: The 2004 Revision Analytical Report. Available: http://www.un.org/esa/population/publications/WPP2004/WPP2004_Vol3_Final/Preface_TOC_ExpNotes.pdf. Accessed 19 October 2009

8. FleissJL

1986 The design and analysis of clinical experiments New York Wiley

9. EfronB

TibshiraniRJ

1993 An introduction to the bootstrap New York Chapman & Hall/CRC Press

10. WhitneyCG

FarleyMM

HadlerJ

HarrisonLH

BennettNM

2003 Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 1737 1746

11. WhitneyCG

PilishviliT

FarleyMM

SchaffnerW

CraigAS

2006 Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 1495 1502

12. EskolaJ

TakalaAK

KilpiTM

LankinenKS

KayhtyH

1998 Clinical evaluation of new pneumococcal vaccines: the Finnish approach. Dev Biol Stand 95 85 92

13. ParkIH

PritchardDG

CarteeR

BrandaoA

BrandileoneMC

2007 Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 45 1225 1233

14. ParkIH

ParkS

HollingsheadSK

NahmMH

2007 Genetic basis for the new pneumococcal serotype, 6C. Infect Immun 75 4482 4489

15. DaganR

2009 Serotype replacement in perspective. Vaccine 27 Suppl 3 C22 C24

16. ConstenlaDGE

Pio de la HozF

O'LoughlinR

SinhaA

ValenciaJE

2009 The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis Washington (D.C.) Sabin Vaccine Institute

17. YaroS

LourdM

TraoréY

Njanpop-LafourcadeBM

SawadogoA

2006 Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis 43 693 700

18. FenollA

GranizoJJ

AguilarL

GiménezMJ

Aragoneses-FenollL

2009 Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 47 1012 1020

19. LagosR

MuñozA

San MartinO

MaldonadoA

HormazabalJC

2008 Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994–2007. J Infect Dis 198 1809 1817

20. KnollMD

MoisiJC

MuhibFB

WonodiCB

LeeEH

2009 Standardizing surveillance of pneumococcal disease. Clin Infect Dis 48 Suppl 2 S37 S48

21. LevineOS

CherianT

HajjehR

KnollMD

2009 Progress and future challenges in coordinated surveillance and detection of pneumococcal and Hib disease in developing countries. Clin Infect Dis 48 Suppl 2 S33 S36

22. RodenburgGD

de GreeffSC

JansenAG

de MelkerHE

SchoulsLM

2010 Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 16 816 823

23. ImöhlM

ReinertRR

van der LindenM

2010 Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992–2008). Int J Microbiol 2010 874189

24. WintherTN

KristensenTD

KaltoftMS

KonradsenHB

KnudsenJD

2009 Invasive pneumococcal disease in Danish children, 1996–2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine. Acta Paediatr 98 328 331

25. World Health Organization 2003 Pneumococcal vaccines. Wkly Epidemiol Rec 78 97 120

26. United Nations 2001 General Assembly, 56th session. Road map towards the implementation of the United Nations millennium declaration: report of the Secretary-General New York New York United Nations

27. PneumoADIP 2008 Pneumococcal Regional Serotype Distribution for Pneumococcal TPP. Available: http://www.vaccineamc.org/files/TPP_Codebook.pdf. Accessed 19 October 2009

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2010 Číslo 10
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#